Anticomplement Therapies for C3 Glomerulopathy and Immune-Complex Membranoproliferative Glomerulonephritis Recurrence - A Dawn of New Hope
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Role of INM004 Shiga-toxin antibodies in treatment of STEC-HUS.
Andreoli S, Monnens L Pediatr Nephrol. 2025; .
PMID: 39909909 DOI: 10.1007/s00467-025-06704-6.
References
1.
Dixon B, Greenbaum L, Huang L, Rajan S, Ke C, Zhang Y
. Clinical Safety and Efficacy of Pegcetacoplan in a Phase 2 Study of Patients with C3 Glomerulopathy and Other Complement-Mediated Glomerular Diseases. Kidney Int Rep. 2023; 8(11):2284-2293.
PMC: 10658235.
DOI: 10.1016/j.ekir.2023.08.033.
View
2.
Servais A, Fremeaux-Bacchi V, Lequintrec M, Salomon R, Blouin J, Knebelmann B
. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet. 2006; 44(3):193-9.
PMC: 2598029.
DOI: 10.1136/jmg.2006.045328.
View
3.
Nester C, Appel G, Bomback A, Bouman K, Cook H, Daina E
. Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies. Am J Nephrol. 2022; 53(10):687-700.
DOI: 10.1159/000527167.
View
4.
Wong E, Nester C, Cavero T, Karras A, le Quintrec M, Lightstone L
. Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. Kidney Int Rep. 2023; 8(12):2754-2764.
PMC: 10719607.
DOI: 10.1016/j.ekir.2023.09.017.
View
5.
Antonucci L, Thurman J, Vivarelli M
. Complement inhibitors in pediatric kidney diseases: new therapeutic opportunities. Pediatr Nephrol. 2023; 39(5):1387-1404.
DOI: 10.1007/s00467-023-06120-8.
View